BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Rifampin

First Posted Date: 2018-10-19

Last Posted Date: 2019-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT03712540

Locations: 🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2

Withdrawn

Conditions: Cancer of the Stomach
Stomach Cancer
Gastric Cancer
Gastroesophageal Junction

Interventions: Biological: Relatlimab + Nivolumab
Biological: Nivolumab
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2018-10-12

Last Posted Date: 2020-05-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03704077

Locations: 🇪🇸
Local Institution, Valencia, Spain

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986177
Other: Placebo (for BMS-986177)
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2018-10-09

Last Posted Date: 2021-09-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT03698513

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-10-04

Last Posted Date: 2022-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 501

Registration Number: NCT03696069

Locations: 🇺🇸
Local Institution, Boston, Massachusetts, United States

Safety Study of Abatacept in Rheumatoid Arthritis Participants

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-10-04

Last Posted Date: 2018-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5800

Registration Number: NCT03696173

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Phase 1

Completed

Conditions: NAFLD
Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease

Interventions: Drug: BMS-986036

First Posted Date: 2018-09-17

Last Posted Date: 2019-10-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT03674476

Locations: 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
🇭🇺
Clinical Research Unit Hungary, Miskolc, Hungary
🇭🇺
PRA Magyarorszag Kft, Budapest, Hungary

and more 1 locations

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-13

Last Posted Date: 2022-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1132

Registration Number: NCT03670667

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Phase 2

Completed

Conditions: Pan Tumor

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2018-09-12

Last Posted Date: 2024-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 212

Registration Number: NCT03668119

Locations: 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇦🇷
Local Institution - 0078, Caba, Argentina
🇺🇸
Broome Oncology, Johnson City, New York, United States

and more 57 locations

Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-10

Last Posted Date: 2022-03-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2052

Registration Number: NCT03663829

A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Completed

Conditions: Kidney Cancer
Renal Cell Carcinoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-10

Last Posted Date: 2022-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 81

Registration Number: NCT03663946

Locations: 🇯🇵
Local Institution, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy